Search Results
Your search for ,aLl matches 18309 pages
Showing 451 - 500Cancer Deaths Expected to Rise to Over 18 Million in 2050
There has been a rapid increase in the global number of cancer cases and deaths between 1990 and 2023, despite advances in cancer treatment and efforts to tackle cancer risk factors over that same period. Without urgent action and targeted funding, 30.5 million people are forecast to receive a new...
Modified FOLFIRINOX vs Gemcitabine/Nab-Paclitaxel in Metastatic Pancreatic Cancer
In a phase II trial (PASS-01) reported in the Journal of Clinical Oncology, Knox et al found similar progression-free survival with modified leucovorin, fluorouracil, irinotecan, oxaliplatin (mFOLFIRINOX) vs gemcitabine/nab-paclitaxel in patients with previously untreated metastatic pancreatic...
Addition of Xevinapant to Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck
In a phase III trial (TrilynX) reported in the Journal of Clinical Oncology, Bourhis et al found that the addition of xevinapant (an inhibitor of apoptosis proteins inhibitor) to platinum-based chemoradiotherapy did not improve event-free survival in patients with unresected locally advanced...
$16 Million PRISM Trial Will Explore AI in Breast Cancer Screening
The University of California, Los Angeles (UCLA) and UC Davis will co-lead a newly funded, multi-institutional clinical trial to evaluate whether artificial intelligence (AI) can help support radiologists in interpreting mammograms more accurately, with the goal of improving breast cancer screening ...
Localized PI3K-Altered Colorectal Cancer: Does Low-Dose Aspirin Reduce the Risk of Recurrence?
In a Scandinavian trial (ALASCCA) reported in The New England Journal of Medicine, Martling et al found that low-dose aspirin reduced the risk of disease recurrence vs placebo in patients with PI3K-altered localized colorectal cancer. Study Details In the double-blind trial, patients with stage I...
Zidesamtinib Shows Activity in Pretreated and Tyrosine Kinase Inhibitor–Naive Patients With ROS1-Positive NSCLC
Zidesamtinib, an investigational oral, highly selective ROS1 tyrosine kinase inhibitor designed to overcome common resistance mechanisms and improve brain penetration, has demonstrated activity in both pretreated and tyrosine kinase inhibitor–naive patients with ROS1-positive non–small cell lung...
Neoadjuvant FOLFIRINOX vs Gemcitabine-Based Chemoradiotherapy in Pancreatic Ductal Adenocarcinoma
In a Dutch phase III trial (PREOPANC-2) reported in The Lancet Oncology, Janssen et al found no difference in overall survival between patients receiving neoadjuvant FOLFIRINOX vs neoadjuvant gemcitabine-based chemoradiotherapy for resectable or borderline resectable pancreatic ductal...
Clonal Hematopoiesis
The ASCO Post is pleased to present Hematology Expert Review, an ongoing feature that quizzes readers on issues in hematology. In this installment, Syed Ali Abutalib, MD, and L. Jeffrey Medeiros, MD, focuses on clonal hematopoiesis of indeterminate potential (also referred to as CHIP) as well as...
Medical Imaging and Risk of Pediatric and Adolescent Hematologic Cancer
In a study reported in The New England Journal of Medicine, Smith-Bindman et al found that medical imaging among children was associated with a significantly increased risk of pediatric and adolescent hematologic cancer. The study involved data from a retrospective cohort of 3,724,623 children born ...
AYA Cancer Survivors Face Increased Social Risks
This year, an estimated 85,500 adolescents and young adults (AYAs) will be diagnosed with cancer in the United States, and about 9,380 AYAs will die from the disease. And while cancer survivorship is increasing for all age groups—there are now nearly 19 million cancer survivors in the United...
HPV Self-Sampling Collection Test Improved Cervical Cancer Screening Rates Among Asian American Women
Studies have shown that human papillomavirus (HPV) infection—especially with high-risk variants such as HPV16 and HPV18—is the primary cause of cervical cancer, accounting for about 95% of all cases. Although cervical cancer screening through Pap smear tests can detect the presence of precancerous...
Amivantamab Plus Lazertinib vs Osimertinib in EGFR-Mutated NSCLC: Overall Survival in MARIPOSA
As reported in The New England Journal of Medicine by Yang et al, the final overall survival analysis in the phase III MARIPOSA trial has shown significant benefit with amivantamab plus lazertinib vs osimertinib in patients with previously untreated EGFR-mutated advanced non–small cell lung cancer...
Surgery for Early-Stage Cancer and Opioid Use
Curative-intent surgery for patients with early-stage cancer led to new, persistent, long-term opioid use in more than 1 in 10 opioid-naive veterans, according to the results of an observational study published in Cancer. The results of the study highlighted how necessary it is to develop new pain...
Does Early Pesticide Exposure Lead to Higher Mortality Risk in Pediatric ALL?
New study findings show that children with acute lymphoblastic leukemia (ALL) who were exposed to pesticides during their mother's pregnancy may have a higher risk of death, according to findings published in Cancers. “This study highlights that exposures in the home environment, even before a...
New NIH-Funded Study Identifies Urine-Based Assay for Prostate Cancer
Researchers have developed a novel method to test for prostate cancer using biomarkers present in urine. This approach may significantly reduce the need for invasive, often painful biopsies, the researchers said in a statement. The study, which was funded in part by the National Institutes of...
ASCO Thanks Richard L. Schilsky, MD, FACP, FSCT, FASCO, for His Vision and Leadership of TAPUR
ASCO extends its thanks and appreciation to Richard L. Schilsky, MD, FACP, FSCT, FASCO, for his decade of leadership and dedication as the inaugural Principal Investigator of the groundbreaking Targeted Agent and Profiling Utilization Registry (TAPUR) Study. The ASCO-sponsored TAPUR study is a...
AACR Cancer Progress Report 2025 Highlights Breakthroughs in Blood Cancers and How NIH Funding Uncertainty Threatens Advances
The 15th edition of the annual AACR Cancer Progress Report presents a mixed picture of the major advances in cancer care over the past year, including the approval of 20 new anticancer drugs, juxtaposed against the continuing rise in early-onset cancers and disparities in care as well as the...
Overall Survival Benefit Shown for Neoadjuvant Nivolumab Plus Chemotherapy in Non–Small Cell Lung Cancer
In the preplanned final analysis of the phase III CheckMate 816 trial, an overall survival benefit has been shown for neoadjuvant nivolumab plus chemotherapy in patients with resectable non–small cell lung cancer (NSCLC).1 Patients treated with the combination experienced an approximate 10%...
Osimertinib Plus Chemotherapy Significantly Prolongs Overall Survival in EGFR-Mutated Advanced NSCLC
The combination of the EGFR-targeting tyrosine kinase inhibitor osimertinib with platinum-based chemotherapy significantly improved overall survival as a first-line treatment for patients with EGFR-mutated, advanced, non–small cell lung cancer (NSCLC) compared with osimertinib monotherapy,...
Use of Pazopanib in Advanced Extrapancreatic Neuroendocrine Tumors
In a phase II trial (Alliance A021202) reported in the Journal of Clinical Oncology, Bergsland et al found that pazopanib prolonged progression-free survival vs placebo in patients with advanced extrapancreatic neuroendocrine tumors (epNETs). However, as stated by the investigators, pazopanib will...
Metastasis-Directed Radiotherapy for Oligometastatic Clear Cell Renal Cell Carcinoma
In a single-center phase II trial reported in The Lancet Oncology, Tang et al found that metastasis-directed radiotherapy without systemic therapy was associated with good outcomes in patients with oligometastatic clear cell renal cell carcinoma. Study Details In the trial, 121 patients...
City of Hope Awarded $23.7 Million to Map Biomarkers in NSCLC
City of Hope® has been awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health (ARPA-H) within the U.S. Department of Health and Human Services. The grant will help City of Hope to create a biomap of tumor changes that cause immunotherapy resistance in advanced ...
Proton Craniospinal Irradiation for Leptomeningeal Metastasis in Lung or Breast Cancer
In an interim analysis of a phase II trial reported in JAMA Oncology, Yang et al found that proton craniospinal irradiation (pCSI) improved central nervous system (CNS) progression-free survival vs photon involved-field radiotherapy (IFRT) in patients who have breast cancer or non–small cell lung...
Overall Survival After Hormonal Therapy vs Hysterectomy in Early Endometrial Cancer
In a U.S. cohort study reported in JAMA Oncology, Suzuki et al assessed long-term survival among premenopausal women with clinical stage I endometrioid endometrial cancer treated with fertility-preserving hormonal therapy vs hysterectomy. Study Details The study focused on National Cancer Database...
Adjuvant Chemoradiotherapy vs Radiotherapy for High-Risk Endometrial Cancer: 10-Year PORTEC-3 Outcomes
In a preplanned 10-year analysis from the phase III PORTEC-3 trial reported in The Lancet Oncology, Post et al found that adjuvant chemoradiotherapy was associated with improved overall survival and recurrence-free survival vs radiotherapy in women with high-risk endometrial cancer. Study Details...
Oral Microbiota and Risk for Pancreatic Cancer
Investigators have found several oral bacteria and fungi associated with an increased risk for pancreatic cancer, according to findings published in JAMA Oncology. This cohort study seems to confirm a long-standing suspicion of the relationship between poor oral health and pancreatic cancer and...
Early Study Results With Novel Bruton’s Tyrosine Kinase Degrader in Relapsed or Refractory Chronic Lymphocytic Leukemia
In a phase I, first-in-human trial of nearly 50 patients with relapsed or refractory B-cell malignancies, the orally administered, small molecule degrader bexobrutideg (NX-5948) was reported to be well tolerated, including in those with a longer duration of treatment and higher doses. Clinical...
Leading Societies Update Clinical Guideline on Postmastectomy Radiation Therapy
Three leading national cancer organizations have issued an updated guideline on postmastectomy radiation therapy (PMRT) for physicians treating patients with breast cancer. The recommendations outline when PMRT is appropriate based on new evidence and evolving clinical practice, and they highlight...
Chronic Toxicity Rates With De-escalated vs Standard Adjuvant Radiotherapy in HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a U.S. two-center phase III trial (MC1675) reported in The Lancet Oncology, Ma et al found that de-escalated adjuvant radiotherapy was associated with a reduced cumulative, chronic grade ≥ 3 toxicity rate at 3 to 24 months after radiotherapy compared with standard adjuvant treatment in patients...
Addition of Metastasis-Directed SBRT to Standard Therapy in Oligometastatic Castration-Resistant Prostate Cancer
In a Canadian phase II trial (GROUQ-PCS 9) reported in The Lancet Oncology, Niazi et al found that the addition of metastasis-directed stereotactic body radiotherapy (SBRT) to standard systemic therapy improved radiographic progression-free survival in patients with oligometastatic...
Nicholas J. Short, MD: Focus on TP53-Mutated ALL
Nicholas J. Short, MD, of The University of Texas MD Anderson Cancer Center, discusses TP53 abnormalities in acute lymphoblastic leukemia (ALL), which are uncommon in pediatric patients but may occur in 10% to 15% of adult patients with ALL. Dr. Short reviews recent research into their impact on...
Incorporating Family Caregivers Into Shared Decision-Making for Patients With Cancer
In a recent study published in JCO Oncology Practice, Steffensen et al examined the process of shared decision-making (SDM) in which clinicians and patients collaborate to make health-care decisions according to the patients’ values, preferences, and medical needs. Although many seriously ill...
Clear-Margin Diagnostic Excisional Biopsy May Adequately Treat Melanoma in Situ, Study Finds
A retrospective cohort study conducted by Dessinioti et al and published in JAMA Dermatology found that, in cases of melanoma in situ, diagnostic excisional biopsy achieving clear margins may be sufficient for treatment. “No local recurrences, metastasis, or melanoma-specific death were observed...
New Liquid Biopsy Test for Early Detection of Head and Neck Cancers
According to the American Cancer Society (ACS), human papillomavirus (HPV)–associated oropharyngeal squamous cell carcinoma (OPSCC) is the most common type of HPV-related malignancy in the United States. In 2025, ACS estimates there will be 59,660 diagnoses of mouth and throat cancers, and about...
Benmelstobart Plus Anlotinib vs Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma
In an interim analysis of a Chinese phase III trial (ETER100) reported in The Lancet Oncology, Zhou et al found that the combination of the PD-L1 inhibitor benmelstobart and anlotinib improved progression-free survival vs sunitinib in the first-line treatment of advanced clear cell renal cell...
ASCO Approves First Guideline on Cancer-Specific Geriatric Assessment of Older Patients in Resource-Limited Settings
On April 22, 2025, an ASCO Expert Panel voted to approve ASCO’s global guideline on geriatric assessment of patients with cancer older than age 65 who are being treated in resource-limited settings or countries.1 Guideline recommendations were informed by the ADAPTE methodology and formal consensus ...
JCO Authorship Guidelines Are of Benefit to Those Caring for Older Patients
The aging population, now the largest group of patients with cancer and cancer survivors, requires a rigorous and focused approach to clinical trial reporting, a need highlighted by the recent author guidelines from the Journal of Clinical Oncology (JCO; Table 1).1 The guidelines are an important...
Noncancer-Related Mortality in RCTs With Targeted Screening
In a meta-analysis reported in JAMA Network Open, Lei et al found a small nonsignificant increase in off-target mortality from noncancer causes or cancers that were not the target of screening in randomized controlled trials (RCTs) with screened and unscreened populations. As stated by the...
Tislelizumab-Based Triplet Therapy for Conversion of Unresectable to Resectable Locally Advanced Biliary Tract Cancer
In a Chinese phase II trial (ZSAB-TransGOLP) reported in The Lancet Oncology, Shi et al found promising results with tislelizumab plus lenvatinib and GEMOX (gemcitabine plus oxaliplatin) chemotherapy (GOLP) in converting unresectable locally advanced biliary tract cancer to resectable disease....
Addition of Neoadjuvant TAR-200 to Cetrelimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
In an interim analysis of a phase II trial (SunRISe-4) reported in The Lancet Oncology, Necchi et al found that the addition of neoadjuvant TAR-200—a targeted releasing system that provides sustained delivery of gemcitabine within the bladder—to the PD-1 inhibitor cetrelimab resulted in a higher...
New ACS Prostate Cancer Report: Late-Stage Incidence Rates Continue to Increase Rapidly as Mortality Declines Slow
The American Cancer Society (ACS) has released Prostate Cancer Statistics, 2025, a report on current prostate cancer occurrence and outcomes in the United States. According to the study, prostate cancer incidence rates have reversed from a decline of 6.4% per year during 2007 through 2014 to an...
How a Novel Coaching Intervention Is Building Resilience and Hope in Adolescents and Young Adults With Advanced Cancer
Each year, nearly 90,000 adolescents and young adults (AYAs; aged 15–39) are diagnosed with cancer, and approximately 9,300 die of the disease.1 And although the 5-year survival rate among these young patients is approaching 80%, it lags behind that of the pediatric population, whose 5-year...
Cardiotoxicity From the Use of Anthracyclines in Cancer Survivors: Preventive Strategies
Many patients from Europe and the United States have experienced the benefits of anthracyclines in the treatment of an array of cancers, including solid tumors such as breast and ovarian cancers as well as lymphoma. However, a number of these cancer survivors will experience severe chronic cardiac...
STAS Predicts Prognosis in Early NSCLC Regardless of Surgical Approach
The presence of tumor spread through air spaces (STAS) demonstrated an association with poor prognosis in patients with early-stage non–small cell lung cancer (NSCLC), whether undergoing segmentectomy or lobectomy, according to findings from an analysis of the phase III JCOG0802/WJOG4607L trial...
New Subcutaneous Amivantamab Combo Dosing Schedule Shows Promising Safety and Efficacy in EGFR-Positive NSCLC
The combination of subcutaneous amivantamab-vmjw every 4 weeks plus daily oral lazertinib led to a high response rate in patients with previously untreated EGFR-mutated advanced non–small cell lung cancer (NSCLC), according to findings from an analysis of cohort 5 of the PALOMA-2 trial presented at ...
Novel Targeted Agent Under Study in MTAP-Deleted NSCLC
BMS-986504, a first-in-class agent targeting MTAP, demonstrated antitumor activity in heavily pretreated patients with MTAP-deleted non–small cell lung cancer (NSCLC), according to findings from the phase I/II CA240-0007 trial presented at the International Association for the Study of Lung Cancer...
Overall Survival Risk for VATS vs Open Lobectomy for Early Lung Cancer
Video-assisted thoracoscopic surgery (VATS) led to a 21% reduction in the risk of death compared with open lobectomy for patients with early-stage lung cancer, in a meta-analysis of randomized trials comparing the two approaches. Results of the meta-analysis were presented at the International...
Lung Cancer Screening May Benefit Adults Up to Age 80 Who Are Fit for Surgery
Older individuals up to the age of 80 who are eligible for lung surgery may achieve a survival benefit from lung cancer screening comparable to that for younger patients, according to the results of a multicenter cohort study from the United Kingdom presented at the International Association for...
Bridging the Gap in Geriatric Oncology Education: A Global Imperative
As the global population ages, oncology faces an urgent challenge: ensuring that health-care professionals are adequately trained to address the unique complexities of cancer care for older adults. Despite the increasing prevalence of cancer in this demographic, geriatric oncology education remains ...
Overcoming the Challenges of Safely Using Opioids to Treat Patients With Chronic Cancer-Related Pain
Research has shown that pain is among the most commonly experienced and feared aspects of a cancer diagnosis.1 It’s easy to understand why. In fact, cancer-related pain is so ubiquitous, between 20% and 50% of patients with early-stage cancer will experience pain,2 and up to 90% of patients with...
